To compare the capacity of ibrutinib (IB) and idelalisib-rituximab (IDELA-R) of prolonging overall survival (OS) as in CLL patients, previously previously treated with chemotherapy only.
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases
Visentin, Andrea;Trentin, Livio;
2021
Abstract
To compare the capacity of ibrutinib (IB) and idelalisib-rituximab (IDELA-R) of prolonging overall survival (OS) as in CLL patients, previously previously treated with chemotherapy only.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
European J of Haematology - 2021 - Morabito - Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed.pdf
non disponibili
Tipologia:
Published (publisher's version)
Licenza:
Accesso privato - non pubblico
Dimensione
392.32 kB
Formato
Adobe PDF
|
392.32 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
